RESEARCH TRIANGLE PARK – GSK CEO Emma Walmsley delivered an upbeat video overview of the drug giant’s latest financial report on Wednesday. And in a statement she further amplified her remarks. But adding to her smile: what the financial report and a positive look ahead could mean for her.
In analyzing the data, Reuters offered this reason for Walmsley to smile:
“The strong results may further help revive investor confidence in CEO Emma Walmsley,” Reuters said.
GSK, which has thousands of employees across the Triangle, upped its guidance fr profits and sales. For the short term, the company “beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines,” Reuters noted.
“We have delivered another excellent quarter of performance, with strong sales and earnings growth, notably in HIV and vaccines, and continued strengthening of the R&D pipeline and product portfolio,” Walmsley said in a statement.
“The approval of Arexvy, the world’s first RSV vaccine, was an important milestone for us and is at the forefront of a next wave in vaccine innovation for GSK. Completion of the Bellus Health acquisition also strengthened our late-stage respiratory pipeline. Our momentum supports the upgrade we have made to our financial guidance for 2023 and further increases our confidence in delivering longer-term profitable growth for shareholders.”
For the complete financial report, read here.
Here’s the video:
